利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.016 秒)

    USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES
    2.
    发明公开
    USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES 有权
    芳香酶抑制剂的用于治疗性腺功能减退症和相关疾病的

    公开(公告)号：EP2753312A1

    公开(公告)日：2014-07-16

    申请号：EP12758965.3

    申请日：2012-09-06

    申请人： Novartis AG

    发明人： TAYLOR, Ann ,  KLICKSTEIN, Lloyd B.

    IPC分类号： A61K9/48 ,  A61K31/4196 ,  A61P5/26 ,  A61P15/08

    CPC分类号： A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

    摘要： This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.

    ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES
    3.
    发明公开
    ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES 审中-公开
    防盗报警器VERFAHRENFÜRWNT-SIGNALWEGBEDINGTE ERKRANKUNGEN

    公开(公告)号：EP2766033A2

    公开(公告)日：2014-08-20

    申请号：EP12794776.0

    申请日：2012-10-12

    申请人： Novartis AG

    发明人： CONG, Feng ,  HAO, Huaixiang ,  KLICKSTEIN, Lloyd B. ,  KWONG, Rou-Fun ,  TAYLOR, Ann ,  XIE, Yang

    IPC分类号： A61K38/17 ,  A61K39/395

    CPC分类号： C07K16/40 ,  A61K31/40 ,  A61K38/53 ,  A61K39/3955 ,  A61K45/06 ,  C12N9/93 ,  C12Y603/02019 ,  A61K2300/00

    摘要： The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of &bgr;-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

    摘要翻译： 跨膜E3泛素连接酶ZNRF3和RNF43是真核细胞中的β-联蛋白和Wnt信号通路的负调节物。 ZNRF3的活性可通过抗体结合其细胞外结构域调节，从而导致Wnt信号传导的增加。 ZNRF3拮抗抗体可用于治疗低Wnt信号传导疾病，如短肠综合征，骨质疏松症，糖尿病，神经变性疾病和粘膜炎。 此外，本发明的拮抗性抗体可用于增强组织修复和伤口愈合的Wnt信号传导。